創薬における人工知能の世界市場

Report Overview

The global market for artificial intelligence (AI) in drug discovery is estimated to increase from $1.6 billion in 2023 to $5.7 billion by 2028, at a compound annual growth rate (CAGR) of 29.6% from 2023 through 2028.

Summary:

The change AI will bring about in drug discovery will take some time. Despite the stunning results of AI-driven innovations, established pharmaceutical corporations still enjoy a number of benefits. Financial resources, specialized scientific expertise, research and development experience, familiarity with regulations, and teams with well-known commercial and branding identities are a few of these. However, some of the incumbency pillars are already showing signs of early deterioration. Massive fundraising efforts and less costly in vitro work are lowering the financial barriers for new research programmes. The ranks of AI natives, who are gradually mimicking the benefits of giant enterprises, are currently being populated by scientists and medical specialists.

Given the revolutionary potential of this technology, pharma companies need to make plans for a future in which AI is frequently utilized in drug research. The applications are varied, and pharma companies must decide where and how AI may most benefit them. Emerging companies are ramping up quickly and adding significant value. In practice, it entails taking the time necessary to comprehend the whole impact that AI is having on R&D, which involves separating hype from genuine achievement and realizing the distinction between standalone software solutions and end-to-end AI-enabled drug development.

The increasing prevalence of chronic diseases is boosting the already growing demand for AI in the drug discovery market. Chronic disease affects hundreds of million patients globally. Approximately 45% of Americas, or 133 million people, suffer from one or more chronic healthcare conditions. Similarly, in Europe, nearly 60 million people have more than one chronic disease. Chronic disease prevalence is expected to rise rapidly in the forecast period (2023-2028), and this is expected to create a significant burden on global healthcare.

Similarly, inorganic strategies amongst market players are also boosting the AI in drug discovery market. For instance, BioNTech SE, a German company that focuses on developing vaccines for infectious diseases as well as cancer medicines such as personalized immunotherapy, acquired InstaDeep, the U.K. based AI start-up engaged in developing a system for making decisions that is intended to train employees and guarantee talent retention. BioNTech acquired InstaDeep for $REDACTED million, and this enabled it to take advantage of the firm’s AI-driven decision-making tools to enhance its own drug discovery and production procedures. This acquisition involves creating personalized cancer vaccines, for which BioNTech and the U.K. government initiated clinical trials on January 6, 2023.

The other vital driving factors are innovation, technological advancements, adoption of AI technologies in pharma industries, and cross-industry collaborations and mergers; these are anticipated to increase the demand for AI in drug discovery during the forecast period. However, limitations associated with AI in drug discovery and shortage of AI workforce will likely impede market growth during the forecast period.

Major players in the AI in the drug discovery markets include Atomwise Inc., BenevolentAI, Exscientia, Insilico Medicine, Recursion Pharmaceuticals and many others. All the major and emerging players are offering a wide range of AI offerings for various therapeutic areas.

Report Scope:

The current report will provide a detailed overview of the AI in the drug discovery market. This report analyzes the market trends associated with AI in drug discovery using data from 2020, estimates from 2021, projections of compound annual growth rates through 2028 (i.e., the forecast period 2023-2028), and information about regional markets of AI in drug discovery. This report will highlight the current and future market potential of AI in drug discovery and provide a detailed analysis of the competitive environment. It will cover regulatory scenarios, drivers, restraints and opportunities as well as market projections for 2028 and the market shares held by key market players.

The scope of the market in this report is segmented into applications, therapeutic areas and region. The applications of AI in drug discovery are further segmented into preclinical testing, target identification, candidate screening and lead optimization, drug repurposing, De novo Drug Design and others. The AI in drug discovery market is segmented by therapeutic area into the following segments: oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, infectious diseases, and others. This report includes a regional market analysis of AI in drug discovery. The market has been segmented by region into various significant geographies: North America, Europe, Asia-Pacific, and the Rest of the World regions. Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Japan, China and India will be covered within the chapter focused on regional segmentation. For market estimates, 2022 serves the base year; forecasts are given from 2023-2028.

The regional market analysis of AI in drug discovery is also covered in this report. The market has been segmented into various significant geographies, including North America, Europe, Asia-Pacific, and other world regions. Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Japan, China, and India will be covered within the regional segment. For market estimates, data will be provided for 2022 because of the base year, with estimates for 2023 and forecast value for 2028.

Report Synopsis

Report Includes:

• 49 data tables and 30 additional tables
• An up-to-date overview and industry analysis of the global markets for artificial intelligence (AI) in drug discovery
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimation of the actual market size and revenue forecast for the AI in drug discovery market, and corresponding market share analysis based on application, therapeutic area, and region
• In-depth information (facts and figures) concerning the major factors influencing the progress of this market (drivers, restraints, opportunities, and industry-specific challenges) with respect to specific growth trends, upcoming prospects, and contributions to the overall market
• Understanding of the importance of ESG in the AI in drug discovery market, consumer attitudes, risks and opportunity assessment, and ESG followed practices by top vendor companies
• Discussion of emerging technologies and new developments in the AI in drug discovery market
• Identification of the major and emerging players who are considered as leaders in the AI in drug discovery market, as well as technological means these companies are using to exploit their markets and dominate the market in their fields
• Review of the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities
• Analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
• Detailed company profiles of the leading market players, including Atomwise Inc., BenevolentAI, Insilico Medicine, Exscientia plc, Recursion Pharmaceuticals Inc., and Schrödinger

Table of Contents

Chapter 1 Introduction
Overview
Artificial Intelligence
Drug Discovery
Artificial Intelligence in Drug Discovery
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Insights
Chapter 3 Market Overview
Introduction
Future Perspectives
Chapter 4 Market Dynamics
Market Drivers
Rising Prevalence of Chronic and Infectious Diseases Globally
Increasing Adoption of AI in Pharmaceutical Sector
Potential of AI in Pharma Sector
Market Restraints
Challenges with AI in Drug Discovery
Market Opportunities
Partnerships and Mergers Between Sectors
Chapter 5 Regulatory Landscape and Reimbursement Scenario
Regulatory Landscape
North America
Europe
Asia-Pacific
Chapter 6 Impact of COVID-19 on Market
Overview
COVID-19 Crisis
COVID-19 Drug Discovery and Vaccine Development Using AI
Impact of COVID-19 on AI in Drug Discovery
COVID-19 Measures
Chapter 7 Market Breakdown by Application
Applications of AI in Drug Discovery
Preclinical Testing
Target Identification
Candidate Screening and Lead Optimization
Drug Repurposing
De Novo Drug Design
Other Applications
Chapter 8 Market Breakdown by Therapeutic Area
AI in Drug Discovery by Therapeutic Area
Oncology
Infectious Diseases
Neurodegenerative Diseases
Cardiovascular Diseases
Metabolic Diseases
Other Diseases
Chapter 9 Market Breakdown by Region
Overview
North America
U.S. Market Size and Forecast
Canadian Market Size and Forecast
Europe
German Market Size and Forecast
U.K. Market Size and Forecast
French Market Size and Forecast
Italian Market Size and Forecast
Spanish Market Size and Forecast
Rest of European Market Size and Forecast
Asia-Pacific
Chinese Market Size and Forecast
Japanese Market Size and Forecast
Indian Market Size and Forecast
South Korean Market Size and Forecast
Rest of Asia-Pacific Market Size and Forecast
Rest of the World
South American Market Size and Forecast
Middle East and African Market Size and Forecast
Chapter 10 ESG Development
Introduction to ESG
Environmental
Social
Government
The Sustainability of AI Suppliers in Drug Discovery Industry
Pharma End User Sustainability in the AI Industry
Case Study
Concluding Remarks from BCC
Chapter 11 Emerging Technologies and Developments
Overview
Current Market Trends
Emerging Technologies
Cell Painting
Quantum Computing
Metabolomics
Chapter 12 M&A and Funding Outlook
M&A Analysis
Major Strategic Alliances
Chapter 13 Competitive Landscape
Competitive Analysis
Vision and Strategy for AI
Technology and Data
External AI Collaborations
Managing Internal Talent
Culture and Methods of Work
Company Share Analysis
Chapter 14 Company Profiles
ARIA PHARMACEUTICALS INC.
ATOMWISE INC.
BENEVOLENTAI
EXSCIENTIA PLC
INSILICO MEDICINE
RECURSION PHARMACEUTICALS INC.
RELAY THERAPEUTICS INC.
SCHRODINGER INC.
XTALPI INC.
Chapter 15 Appendix: Acronyms

List of Tables
Summary Table : Global Market for AI in Drug Discovery, by Application, Through 2028
Table 1 : Global Totals of Angina Pectoris and Stroke Survivors, Through 2030
Table 2 : Global Incidence and Prevalence of All Stroke Types, 2019
Table 3 : Global Prevalence of Congestive Heart Failure and Stroke, Through 2030
Table 4 : Global Diabetes Prevalence, Estimates and Projections, 2019-2045
Table 5 : Cases of Diabetes Worldwide, by Type, 2019
Table 6 : Global Prevalence of Diabetes, by Type, Through 2040
Table 7 : Global Prevalence of Breast Cancer Cases, by Country/Region, Through 2025
Table 8 : Global Epidemiology of Colorectal Cancer, by Region, Through 2030
Table 9 : Global Occurrences of Deaths, by Various Cancer Types, Through 2030
Table 10 : Breakdown of Global Deaths Due to Cancer, by Various Cancer Types, 2021
Table 11 : Prevalence of Multiple Sclerosis, by Region, 2013 and 2020
Table 12 : Global Prevalence of Symptomatic Key Musculoskeletal Disorders, Through 2025
Table 13 : Global Occurrences of Deaths, by Various Musculoskeletal Disorders, Through 2030
Table 14 : Global Occurrences of Deaths from Digestive Diseases, by Region, Through 2025
Table 15 : Global HIV Epidemic, by Age Group, 2020
Table 16 : Global Market for AI in Drug Discovery, by Application, Through 2028
Table 17 : Global Market for AI in Preclinical Testing Application, by Region, Through 2028
Table 18 : Global Market for AI in Target Identification Application, by Region, Through 2028
Table 19 : Global Market for AI in Candidate Screening and Lead Optimization Application, by Region, Through 2028
Table 20 : Global Market for AI in Drug Repurposing Application, by Region, Through 2028
Table 21 : Global Market for AI in De Novo Drug Design Application, by Region, Through 2028
Table 22 : Global Market for AI in Other Drug Discovery Applications, by Region, Through 2028
Table 23 : Global Market for AI in Drug Discovery, by Therapeutic Area, Through 2028
Table 24 : Global Market for AI in Drug Discovery for Oncology, by Region, Through 2028
Table 25 : Global Market for AI in Drug Discovery in Infectious Diseases, by Region, Through 2028
Table 26 : Global Market for AI in Drug Discovery in Neurodegenerative Diseases, by Region, Through 2028
Table 27 : Global Market AI in Drug Discovery in Cardiovascular Diseases, by Region, Through 2028
Table 28 : Share of Global Diabetes Cases, by Type
Table 29 : Global Market for AI in Drug Discovery in Metabolic Diseases, by Region, Through 2028
Table 30 : Global Market for AI in Drug Discovery in Other Diseases, by Region, Through 2028
Table 31 : Global Market for AI in Drug Discovery, by Region, Through 2028
Table 32 : Diabetes Estimates in North America, by Country, 2000-2045
Table 33 : Influenza Disease Burden in the U.S., by Age Group, 2019-2020 Influenza Season
Table 34 : North American Market for AI in Drug Discovery, by Country, Through 2028
Table 35 : Diabetes Estimates in Europe, by Country, 2000-2045
Table 36 : European Market for AI in Drug Discovery, by Country, Through 2028
Table 37 : Tuberculosis Burden of Asian Countries, by Country, 2019
Table 38 : Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
Table 39 : Asia-Pacific Market for AI in Drug Discovery, by Country, Through 2028
Table 40 : Diabetes Estimates in the RoW, by Country, 2000-2045
Table 41 : Estimation of New Cancer Cases in Africa, by Cancer Type, 2020 and 2024
Table 42 : Rest of the World Market for AI in Drug Discovery, by Sub-region, Through 2028
Table 43 : Key Focus Areas in ESG Metrics
Table 44 : ESG Rankings for Few AI Companies for Drug Discovery, 2023
Table 45 : ESG Rankings for Major Pharma Companies Utilizing AI for Drug Discovery, 2023
Table 46 : Major Strategic Alliances, AI in Drug Discovery Market, 2018-2023
Table 47 : Aria Pharmaceuticals: Pipeline Products
Table 48 : Aria Pharmaceuticals: AI Offerings
Table 49 : Atomwise: Pipeline Products
Table 50 : Atomwise: AI Offerings
Table 51 : Atomwise: News/Developments, 2019-2022
Table 52 : BenevolentAI: Pipeline Products
Table 53 : BenevolentAI: AI Offerings
Table 54 : BenevolentAI: Annual Revenue, 2022
Table 55 : Benevolent AI: News/Developments, 2019-2023
Table 56 : Exscientia Plc: Pipeline Products
Table 57 : Exscientia Plc: AI Offerings
Table 58 : Exscientia Plc: Annual Revenue, 2022
Table 59 : Exscientia Plc: News/Developments, 2021-2022
Table 60 : Insilico Medicine: Pipeline Products
Table 61 : Insilico Medicine: AI Offerings
Table 62 : Insilico Medicine: News/Developments, 2021-2023
Table 63 : Recursion: Pipeline Products
Table 64 : Recursion: AI Offerings
Table 65 : Recursion: Annual Revenue, 2022
Table 66 : Recursion: News/Developments, 2021-2023
Table 67 : Relay Therapeutics: Pipeline Products
Table 68 : Relay Therapeutics: AI Offerings
Table 69 : Relay Therapeutics: Annual Revenue, 2022
Table 70 : Relay Therapeutics: News/Developments, 2019-2022
Table 71 : Schrödinger: Pipeline Products
Table 72 : Schrödinger: Pipeline Products – II Collaborative Programs
Table 73 : Schrödinger: AI Offerings
Table 74 : Schrödinger: Annual Revenue, 2022
Table 75 : Schrödinger: News/Developments, 2020-2022
Table 76 : XtalPi: AI Offerings
Table 77 : XtalPi: News/Developments, 2021-2023
Table 78 : Acronyms Used in This Report

List of Figures
Summary Figure : Global Market Shares of AI in Drug Discovery, by Application, 2022
Figure 1 : Traditional vs. AI-Based Drug Delivery Techniques
Figure 2 : Timeline of AI in Drug Discovery Industry
Figure 3 : Growth of AI in Drug Discovery in Initial Phases, 2013-2021
Figure 4 : Breakdown of Worldwide Diabetes Cases, by Type, 2019
Figure 5 : Global Prevalence of Diabetes, by Type, 2018 and 2040
Figure 6 : Breakdown of New Cancer Cases in Women, by Cancer Type, 2020
Figure 7 : Breakdown of New Cancer Cases in Men, by Cancer Type, 2020
Figure 8 : Global Prevalence of Breast Cancer Cases, by Country/Region, 2015-2025
Figure 9 : Global Epidemiology of Colorectal Cancer, by Region, 2000-2030
Figure 10 : Global Occurrences of Deaths, by Various Cancer Types, 2000-2030
Figure 11 : Breakdown of Global Deaths Due to Cancer, by Various Cancer Types, 2021
Figure 12 : Global Prevalence of Symptomatic Key Musculoskeletal Disorders, by Region, 2018
Figure 13 : Breakdown of Global Occurrences of Deaths, by Various Musculoskeletal Disorders, 2015
Figure 14 : Global Occurrences of Deaths from Digestive Diseases, by Region, 2015-2025
Figure 15 : Top Pharma Companies AI Deals, by Company, 2020
Figure 16 : Top AI and Tech Partners and Pharma Deals, by Company, 2020
Figure 17 : Applications of AI in Drug Discovery
Figure 18 : Global Market for AI in Preclinical Testing Application, 2020-2028
Figure 19 : Global Market for AI in Target Identification Application, 2020-2028
Figure 20 : Global Market for AI in Candidate Screening and Lead Optimization Application, 2020-2028
Figure 21 : Drug Repurposing Approaches
Figure 22 : Global Market for AI in Drug Repurposing Application, 2020-2028
Figure 23 : Global Market for AI in De Novo Drug Design Application, 2020-2028
Figure 24 : Global Market for AI in Other Drug Discovery Applications, 2020-2028
Figure 25 : Global Market for AI in Drug Discovery for Oncology, 2020-2028
Figure 26 : Global Market for AI in Drug Discovery in Infectious Diseases, 2020-2028
Figure 27 : Global Market for AI in Drug Discovery in Neurodegenerative Diseases, 2020-2028
Figure 28 : Global Market for AI in Drug Discovery in Cardiovascular Diseases, 2020-2028
Figure 29 : Share of Global Diabetes Cases, by Type
Figure 30 : Global Market for AI in Drug Discovery in Metabolic Diseases, 2020-2028
Figure 31 : Global Market for AI in Drug Discovery in Other Diseases, 2020-2028
Figure 32 : Global Market Shares of AI in Drug Discovery, by Region, 2022
Figure 33 : North American Market for AI in Drug Discovery, by Country, 2020-2028
Figure 34 : Share of Cancer Diagnosis in Europe, by Gender, 2020
Figure 35 : European Market for AI in Drug Discovery, by Country, 2020-2028
Figure 36 : Asia-Pacific Market for AI in Drug Discovery, by Country, 2020-2028
Figure 37 : Rest of the World Market for AI in Drug Discovery, by Sub-region, 2020-2028
Figure 38 : How a Strong ESG Proposition Benefits Businesses
Figure 39 : ESG-Adoption Level Across All the Industries, Global, 2021 and 2022
Figure 40 : The Ten Business Sustainability Trends Identified for 2022
Figure 41 : Key Sustainable Practices Being Implemented in Research Laboratories
Figure 42 : ESG Commitments of Recursion
Figure 43 : Emerging Technologies in the AI in Drug Discovery Market
Figure 44 : Venture Capital Deals Including Corporate Pharma and Biotech Investors, by Year, 2013-2022
Figure 45 : Investments in the AI in Drug Discovery Industry, by Year, 2014-2020
Figure 46 : Shares of Global Market for AI in Drug Discovery, by Company, 2022
Figure 47 : BenevolentAI: Annual Revenue, 2021 and 2022
Figure 48 : Exscientia Plc: Annual Revenue, 2021 and 2022
Figure 49 : Exscientia Plc: Revenue Share, by Country/Region, 2022
Figure 50 : Recursion: Annual Revenue, 2021 and 2022
Figure 51 : Relay Therapeutics: Annual Revenue, 2021 and 2022
Figure 52 : Schrödinger: Annual Revenue, 2021 and 2022
Figure 53 : Schrödinger: Revenue Share, by Segment, 2022
Figure 54 : Schrödinger: Revenue Share, by Region/Country, 2022